The Impact of Reproductive Issues on Preferences of Women with Relapsing Multiple Sclerosis for Disease-Modifying Treatments

被引:6
|
作者
Webb, Edward J. D. [1 ]
Meads, David M. [1 ]
Eskyte, Ieva [2 ]
Ford, Helen L. [3 ]
Bekker, Hilary L. [1 ]
Chataway, Jeremy [4 ,5 ]
Pepper, George [6 ]
Marti, Joachim [7 ]
Okan, Yasmina [8 ]
Pavitt, Sue H. [9 ]
Schmierer, Klaus [10 ,11 ]
Manzano, Ana [12 ]
机构
[1] Univ Leeds, Leeds Inst Hlth Sci, Leeds, W Yorkshire, England
[2] Univ Leeds, Sch Law, Leeds, W Yorkshire, England
[3] Leeds Teaching Hosp NHS Trust, Leeds, W Yorkshire, England
[4] UCL, Queen Sq Multiple Sclerosis Ctr, Dept Neuroinflammat, UCL Queen Sq Inst Neurol,Fac Brain Sci, London WC1B 5EH, England
[5] Univ Coll London Hosp, Biomed Res Ctr, Natl Inst Hlth Res, London, England
[6] ShiftMs, London, England
[7] Univ Lausanne, Ctr Primary Care & Publ Hlth Unisante, Lausanne, Switzerland
[8] Univ Leeds, Leeds Univ, Ctr Decis Res, Business Sch, Leeds, W Yorkshire, England
[9] Univ Leeds, Sch Dent, Dent Translat & Clin Res Unit, Leeds, W Yorkshire, England
[10] Queen Mary Univ London, Barts & London Sch Med & Dent, Blizard Inst Neurosci Surg & Trauma, London, England
[11] Barts Hlth NHS Trust, Royal London Hosp, Clin Board Med Neurosci, London, England
[12] Univ Leeds, Sch Sociol & Social Policy, Leeds, W Yorkshire, England
来源
关键词
DISCRETE-CHOICE EXPERIMENTS; CONJOINT-ANALYSIS; PROFESSIONALS PREFERENCES; PATIENT PREFERENCES; PREGNANCY; THERAPIES; DIAGNOSIS; ATTRIBUTES; PEOPLE; TESTS;
D O I
10.1007/s40271-020-00429-4
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background Relapsing-remitting multiple sclerosis (RRMS) is an incurable disease characterised by relapses (periods of function loss) followed by full or partial recovery, and potential permanent disability over time. Many disease-modifying treatments (DMTs) exist that help reduce relapses and slow disease progression. Most are contraindicated during conception/pregnancy and some require a discontinuation period before trying to conceive. Although around three-quarters of people with RRMS are women, there is limited knowledge about how reproductive issues impact DMT preference. Objective The aim of this study was to measure the preferences for DMTs of women with RRMS who are considering pregnancy. Design An online discrete choice experiment (DCE). Methods Participants chose between two hypothetical DMTs characterised by a set of attributes, then indicated if they preferred their choice to no treatment. Attributes were identified from interviews and focus groups with people with RRMS and MS professionals, as well as literature reviews, and included the probability of problems with pregnancy, discontinuation of DMTs, and breastfeeding safety. In each DCE task, participants were asked to imagine making decisions in three scenarios: now; when trying to conceive; and when pregnant. Analysis Two mixed logit models were estimated, one to assess the statistical significance between scenarios and one in maximum acceptable risk space to allow comparison of the magnitudes of parameters between scenarios. Sample Women with RRMS who were considering having a child in the future, recruited from a UK MS patient register. Results Sixty respondents completed the survey. Participants preferred no treatment in 12.6% of choices in the 'now' scenario, rising significantly to 37.6% in the 'trying to conceive' scenario and 60.3% in the 'pregnant' scenario (Kruskal-Wallisp < 0.001). This pattern corresponds with results from models that included a no-treatment alternative-specific constant (ASC) capturing differences between taking and not taking a DMT not specified by the attributes. The ASC was lower in the trying to conceive scenario than in the now scenario, and lower still in the pregnant scenario, indicating an intrinsic preference for no treatment. Participants also placed relatively less preference on reducing relapses and avoiding disease progression in the trying to conceive and pregnant scenarios compared with a lower risk of problems with pregnancy. In the trying to conceive scenario, participants' preference for treatments with shorter washout periods increased. Conclusion Women with RRMS considering having a child prefer DMTs with more favourable reproduction-related attributes, even when not trying to conceive. Reproductive issues also influenced preferences for DMT attributes not directly related to pregnancy, with preferences dependent on the life circumstances in which choices were made. The design of the DCE highlights the benefits of considering the scenario in which participants make choices, as they may change over time.
引用
收藏
页码:583 / 597
页数:15
相关论文
共 50 条
  • [1] The Impact of Reproductive Issues on Preferences of Women with Relapsing Multiple Sclerosis for Disease-Modifying Treatments
    Edward J. D. Webb
    David Meads
    Ieva Eskytė
    Helen L. Ford
    Hilary L. Bekker
    Jeremy Chataway
    George Pepper
    Joachim Marti
    Yasmina Okan
    Sue H. Pavitt
    Klaus Schmierer
    Ana Manzano
    [J]. The Patient - Patient-Centered Outcomes Research, 2020, 13 : 583 - 597
  • [2] Established disease-modifying treatments in relapsing-remitting multiple sclerosis
    Oh, Jiwon
    O'Connor, Paul W.
    [J]. CURRENT OPINION IN NEUROLOGY, 2015, 28 (03) : 220 - 229
  • [3] Update on Disease-Modifying Treatments for Multiple Sclerosis
    Carrithers, Michael D.
    [J]. CLINICAL THERAPEUTICS, 2014, 36 (12) : 1938 - 1945
  • [4] Disease-modifying treatments for progressive multiple sclerosis
    Comi, Giancarlo
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 1428 - 1436
  • [5] Preferences of German physicians for features of injectable, oral, and infused disease-modifying treatments for relapsing-remitting multiple sclerosis
    Poulos, C.
    Wakeford, C.
    Kinter, E.
    Mange, B.
    Schenk, T.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 326 - 326
  • [6] Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis
    Lebrun, Christine
    Debouverie, Marc
    Vermersch, Patrick
    Clavelou, Pierre
    Rumbach, Lucien
    de Seze, Jerome
    Wiertlevski, Sandrine
    Defer, Gilles
    Gout, Olivier
    Berthier, Frederic
    Danzon, Arlette
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2008, 14 (03) : 399 - 405
  • [7] Postpartum Relapse Rates in Women with Relapsing Multiple Sclerosis and the Impact of Disease-modifying Drugs: A Systematic Review
    Hellwig, Kerstin
    Di Cantogno, Elisabetta Verdun
    Sabido, Meritxell
    [J]. NEUROLOGY, 2021, 96 (15)
  • [8] Early Disease-Modifying Treatments for Presymptomatic Multiple Sclerosis
    Zeydan, Burcu
    Azevedo, Christina J.
    Makhani, Naila
    Cohen, Mikael
    Tutuncu, Melih
    Thouvenot, Eric
    Siva, Aksel
    Okuda, Darin T.
    Kantarci, Orhun H.
    Lebrun-Frenay, Christine
    [J]. CNS DRUGS, 2024,
  • [9] Cancer and multiple sclerosis in the era of disease-modifying treatments
    Lebrun, Christine
    Vermersch, Patrick
    Brassat, David
    Defer, Gilles
    Rumbach, Lucien
    Clavelou, Pierre
    Debouverie, Marc
    de Seze, Jerome
    Wiertlevsky, Sandrine
    Heinzlef, Olivier
    Tourbah, Ayman
    Fromont, Agnes
    Frenay, Marc
    [J]. JOURNAL OF NEUROLOGY, 2011, 258 (07) : 1304 - 1311
  • [10] Disease-modifying treatments for patients with multiple sclerosis in Spain
    Perez, Alejandro Santiago
    Casado, Santos Esteban
    Payero, Miriam Alvarez
    Pueyo, Angel Escolano Escolano
    Bernabe, Angel Guillermo Arevalo
    Zamora, Nuria Padulles
    Ruiz, Pilar Diaz
    Gonzalez, Ana Maria Lopez
    [J]. FARMACIA HOSPITALARIA, 2023, 47 (04) : 155 - 160